Skip to content

Stock-Based Comp at other companies

Abbott logo
AbbottABT
$317M+9.7%
Danaher logo
DanaherDHR
$58M-4.9%
Revvity logo
RevvityRVTY
$8.72M+12.7%
Quest Diagnostics logo
Quest DiagnosticsDGX
$20M-9.1%
Opko Health logo
Opko HealthOPK
$2.74M+4.5%
Agilent Technologies logo
Agilent TechnologiesA
$32M+6.7%

Other financials

Income statement

See full
Revenue$619.8M-10.5%
Gross profit$263.8M-23.2%
Operating income-$31.8M-198%
Net income-$91.8M-623%
EPS (diluted)-$1.35-611%

Balance sheet

See full
Cash & equivalents$140.4M+10.4%
Total debt$3.1B+0.3%
Total equity$1.9B-38.2%
Total assets$5.6B-12.9%

Cash flow

See full
Operating cash flow-$33.0M-150%
CapEx$34.0M-39.5%
Free cash flow-$67.0M-813%

Valuation

See full
Market cap$921.94M-51.4%
Enterprise value$3.88B-20.1%
P/S0.4×-0.3×

Profitability

See full
Gross margin45%-2.0pp
Operating margin-37%-46.2pp
Net margin-45.6%-75.7pp
FCF margin13.8%

Returns & leverage

See full
Return on equity-49.9%-70.8pp
Debt / equity1.7×+0.6×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: QuidelOrtho Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about QuidelOrtho Corporation's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is QuidelOrtho Corporation's stock-based comp?
QuidelOrtho Corporation (QDEL) reported stock-based comp of $10.7M in Q1 2026.
How has QuidelOrtho Corporation's stock-based comp changed year-over-year?
QuidelOrtho Corporation's stock-based comp decreased by 7.8% year-over-year, from $11.6M to $10.7M.
What is the long-term trend for QuidelOrtho Corporation's stock-based comp?
Over 3 years (2022 to 2025), QuidelOrtho Corporation's stock-based comp has grown at a -1.8% compound annual growth rate (CAGR), from $48.4M to $45.9M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.